Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Overview of attention for article published in Lancet Neurology, October 2026

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

bluesky: 3 Bluesky users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 1 X post from an account with 53,182 followers.

Prof Merit E Cudkowicz and colleagues report the results of a phase 2 RCT that aimed to evaluate the safety, tolerability, and efficacy of SAR443820 in participants with ALS, highlighting the ongoing challenges in identifying effective treatments: https…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.